LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC
Alex Martínez‐Martí, Margarita Majem, Fabrice Barlési, E. Carcereny Costa, Quincy Chu, I. Monnet, Ángel Rodríguez Sánchez, Shaker Dahkil, D. Ross Camidge, Philip He, Yee Soo-Hoo, Zachary A. Cooper, Rakesh Kumar, John Bothos, Charu Aggarwal, Roy S. Herbst
Topics & Concepts
DurvalumabMedicineStage (stratigraphy)OncologyInternal medicinePhases of clinical researchOpen labelClinical trialCancerNivolumabPaleontologyImmunotherapyBiologyEsophageal Cancer Research and TreatmentLung Cancer Treatments and MutationsLymphoma Diagnosis and Treatment